CIPLA
Investment Focus - Cipla: Buy Srividhya Sivakumar November 26, 2011: Investors looking for long-term additions to their portfolio can use the ongoing market correction to accumulate the stock of Cipla. Improving financial performance, better utilisation of its newly set up manufacturing facility at Indore SEZ, besides promising growth prospects make the stock an attractive investment bet. At the current market price of Rs 316, the stock trades at about 20 times its likely FY13 per share earnings. This seems justified considering the company's strong generic pipeline, entry into bio-similars and the likely commercialisation of its CFC-free inhalers in the next couple of years. A manageable debt on its books is also a positive. In the quarter ended September 2011, Cipla reported a 10 per cent increase in sales to Rs 1,732 crore and 17 per cent increase in profits to Rs 309 crore. While its domestic business grew by about 12 per cent (48 per cent of total sales), exports